NCT02223039 - A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL

AbGn-168H

AbGn-168H monoclonal antibody

BIOLOGICAL

Placebo

Placebo of AbGn-168H

Trial Locations (15)

10016

Manhattan Medical Research Practice PLLC, New York

14623

Skin Search of Rochester, Inc., Rochester

27265

High Point Clinical Trials Cente, High Point

27612

Wake Research Associates, Raleigh

29650

Radiant Research, Inc., Greer

32127

Progressive Medical Research, Port Orange

33609

Progressive Medical Research, Tampa

34471

Renstar Medical Research, Ocala

46256

DawesFretzin Clinical Research Group, LLC., Indianaopolis

72758

Northwest AR Clinical Trials Center, PLLC., Rogers

73112

Lynn Health Science Institute, Oklahoma City

77494

Suzanne Bruce and Associates, P.A., The Center for Skin Research, Katy

84132

University of Utah Dermatology School of Medicine Dermatology 4A330, Salt Lake City

85032

Alliance Dermatology & MOHS Center, PC, Phoenix

08009

Comprehensive Clinical Research, Berlin

All Listed Sponsors

lead

AbGenomics B.V Taiwan Branch

INDUSTRY